AdvaMed’s Response to the GenAI Discussion Paper
AdvaMed submitted comments to the U.S. Food and Drug Administration in response to FDA’s discussion paper on the regulation of generative AI-enabled medical devices (Docket No. FDA-2026-N-7874). The comments reflect AdvaMed’s position on how FDA should approach oversight of GenAI devices, building on existing regulatory frameworks to support innovation while protecting patients.